Medical Terminology


« Back to Glossary Index

Reboxetine (Davedex, Edronax, Irenor, Norebox, Prolift, Solvex, Yeluoshu, Zuolexin) belongs to a group of medicines called norepinephrine reuptake inhibitors (NRIs), and is marketed as an antidepressant for the use in the treatment of major depression. Reboxetine is very similar to atomoxetine. Although reboxetine is approved for use in Europe and elsewhere, it is not currently approved in the U.S. However, in October 2018, the U.S. FDA granted Orphan Drug Designation (ODD) status to Axsome Therapeutics’ AXS-12 (reboxetine) for the treatment of narcolepsy symptoms. Read more about reboxetine on HF’s Treatment web page HERE.

Davedex, Edronax, Irenor, Norebox, Prolift, Solvex, Yeluoshu, Zuolexin

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.